Completion of new facility in San Diego
Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational.
Trading update for the year 2023
The Company announces a trading update to its shareholders.
Launch of Commercial Single Cell Proteomics Services
Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents.
Investor Presentation
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on 19th September 2023 at 10:00am BST.
Interim results for the six months ended 30 June 2023
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2023.
Repayment of Loan to Vulpes Investment Management Private Limited
The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling £824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 p.m. today, all resolutions were duly passed.
Proteome Sciences expands into the US: New Facility to open in San Diego
Proteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America (“US”).